1. Introduction {#sec1}
===============

Pattern Identification (PI) is a unique diagnosis system of traditional medicine practiced in East Asian countries including China, Korea, and Japan and provides information that guides appropriate treatment of patient disease. Previous reports described how traditional Korean medicine (TKM) categorizes stroke as four patterns according to their symptoms and sign: Qi deficiency (QD), Dampness-phlegm (DP), Yin deficiency (YD), and Fire and Heat (FH) \[[@B1]\]. Among them, the DP pattern is attributed to the prevention of Qi-blood circulation in the body, resulting in a pathological product \[[@B2]\]. Most notably, the DP pattern is associated with overweight/obesity and dyslipidemia \[[@B3]--[@B6]\]. Kim et al. reported that body mass index (BMI) of subjects with DP pattern was significantly increased compared with subjects exhibiting other patterns \[[@B5]\], and Kang et al. showed that the levels of total cholesterol, LDL-cholesterol and triglycerides in serum of subjects displaying the DP pattern were also higher than subjects with non-DP pattern \[[@B6]\].

However, the diagnosis of PI depends on symptoms/sign exhibited by patients, which may be interpreted incorrectly. Therefore, it is necessary to establish scientific evidence to aid accurate diagnosis based on PI. Previously, several studies showing relation between biological factors and PI were reported \[[@B7]--[@B13]\]. In particular, NPY and UCP2 and PON1, related with obesity and dyslipidemia, were significantly associated with DP pattern in Korean stroke patients \[[@B8], [@B9], [@B13]\].

Metabolomics provides a powerful approach for global and quantitative assessment of endogenous small molecule metabolites within biological fluids \[[@B14]\] and has been utilized to propose candidate biomarkers of several diseases \[[@B15]--[@B20]\]. Metabolites are the small chemical compounds or products involved in various metabolic pathways, and the changes of their levels serve as indicators of changes of pathology or physiology \[[@B14]\]. Recently, metabolomics investigations were performed to explain PI of rheumatoid arthritis and type 2 diabetes in Chinese populations \[[@B21], [@B22]\].

In this study, we analyzed metabolic profiles in plasma of acute patients with cerebral infarction (CI) by ultrahigh-performance liquid chromatography/time-of-flight mass spectrometry (UHPLC-TOFMS) and searched for metabolites differing in levels between DP and non-DP patterns.

2. Materials and Methods {#sec2}
========================

2.1. Study Subjects {#sec2.1}
-------------------

This study was collected as parts of the project "The Fundamental Study for the Standardization and Objectification of PI in TKM for Stroke (SOPI-Stroke)" in the Korean Institute of Oriental Medicine (KIOM) \[[@B23]\].

Patients with CI were admitted from 2009 to 2010 to the following Korean oriental medical hospitals participating in this study: Kyung Hee Oriental Medical Center (Seoul), Kyung Hee East-West Neo Medical Center (Seoul), Dong Guk International Hospital (Kyunggi-do), and Dae Jeon Oriental Medical Hospital (Daejeon). Subjects had to be enrolled as CI patients within three days of the onset, and their symptoms were confirmed by imaging diagnosis, using computerized tomography (CT), magnetic resonance imaging (MRI), or magnetic resonance angiography (MRA). CI subtypes were classified as large artery atherosclerosis (LAA), cardioembolism (CE), small vessel occlusion (SVO), stroke of other determined etiology (SOE), and stroke of undetermined etiology (SUE) subtype according to the trial of ORG 10172 in the Acute Stroke Treatment (TOAST) classification. Subjects with subarachnoid, subdural, or epidural hemorrhage were excluded in this study, and subjects with diabetes mellitus and stroke in history and with infectious diseases and liver diseases were also excluded.

After obtaining written informed consent from all subjects, clinical data were collected. This study was approved by the Institutional Review Boards (IRB) of the KIOM and by each of the oriental medical hospitals.

2.2. PI Diagnosis of CI Patients {#sec2.2}
--------------------------------

The symptoms and signs of subjects were collected using "stroke PI case report form" \[[@B2]\], and PI diagnosis of subjects was determined by two expert TKM doctors based on "Korean Standard PIs for Stroke-III" previously reported by Lee et al. \[[@B1]\]. Subjects receiving differing diagnoses from the two doctors were excluded. The number of patients was 68 in non-DP and 73 in DP.

2.3. Plasma Preparation {#sec2.3}
-----------------------

Preparation of plasma from each subject for UHPLC-MS analysis was performed according to protocols provided by Human Serum Metabolome (HUSERMET) Consortium \[[@B24]\]. Briefly, 200 *μ*L of plasma thawed on ice was thoroughly mixed with 600 *μ*L methanol and 100 *μ*L of internal standard solution and centrifuged at 15000 g for 15 min at 25°C. Supernatant was transferred and completely dried by using centrifugal vacuum evaporator over 4 hours. Dried samples were resolved by adding 100 *μ*L of melting solution (acetonitrile/isopropanol/water, 3 : 2 : 2) and centrifuged at 15000 g for 15 min at 25°C. Supernatant was transferred into vial and used for UHPLC-MS analysis.

2.4. Metabolic Profiling Analysis by UHPLC-MS {#sec2.4}
---------------------------------------------

A 10 *μ*L aliquot of the concentrated plasma extract was injected into an Ascentis Express C18 column (10 cm × 2.1 mm, 2.7 *μ*m particles: Supelco, Bellefonte, PA, USA) using a SIL-5000 autosampler (Shimadzu, Tokyo, Japan). The solvent was delivered by LC-20AD pumps (Shimadzu Co., Tokyo, Japan) at a flow rate of 0.4 mL/min, with solvent A being 0.15% aqueous formic acid and solvent B being acetonitrile/isopropanol (2 : 1). Gradient elution was performed and equilibrated with water containing 0.15% formic acid. Samples were eluted by gradient containing 0.15% formic acid for 30 min, and metabolites separated by UHPLC were assigned by MS (Waters, Milford, MA, USA). Separate injections were made for analyses conducted ESI-positive and ESI-negative modes.

The voltage of capillary and sampling cone was, respectively, set at 3 kV and 10 V, and the desolvation flow was set to 350 L/h at a temperature of 350°C. The source temperature was set to 100°C. Collecting range of MS data was *m*/*z* 100--2000 with a scan time of 0.2 s. The accurate mass and composition for the metabolite ions were calculated by MassLynx 4.1 (Waters, Milford, MA, USA) incorporated in the instrument.

2.5. Data Processing and Identification of Metabolites {#sec2.5}
------------------------------------------------------

Results from UHPLC-MS analyses were processed using automated peak detection, integration, and retention time alignment using MarkerLynx 4.1 software (Waters, Milford, MA, USA), and MS data were assembled into a matrix of integrated extracted ion chromatogram peak areas, organized by mass and retention time. Parameters for MarkerLynx analysis were set as follows: peak width at 5% height: 15 s, intensity threshold: 20, mass window: 0.1 amu, retention time window: 0.5 min, noise elimination level: 6, mass tolerance: 0.1 Da. Normalization of MS spectra was performed by total normalization, and peaks not detected from over 2% of subjects were excluded in the following analysis. Metabolites were annotated using searches of the ChemSpider database (<http://www.chemspider.com/>) and Human Metabolome Database Version 2.5 (<http://www.hmdb.ca/>) or/and confirmed by external standards based on retention time and mass spectra.

2.6. Statistical Analysis {#sec2.6}
-------------------------

The statistical analysis of our data was performed with IBM SPSS Statistics 19 (IBM Co., New York, NC, USA). Normality of continuous variables in clinical data was decided by Kolmogorov-Smirnov test, and statistical difference was determined by *t*-test in parametric variable or Mann-Whitney *U* test in nonparametric variable. Categorical variables were compared with a chi-squared test or Fisher\'s exact test. Results of MS analysis were represented as the mean ± SD, and the difference in mass intensity of plasma metabolites between the two groups was tested by independent *t*-test with Mann-Whitney *U* test. The statistical significance was set at *P* \< 0.05.

3. Results {#sec3}
==========

The general characteristics between non-DP and DP were shown in [Table 1](#tab1){ref-type="table"}. The mean age of the DP pattern patients was slightly higher than that of the non-DP pattern patients. BMI in body composition and total cholesterol and LDL-cholesterol in serum parameters also showed higher levels in the DP pattern patients, which was similar to previous reports by Kim et al. and Lim et al. \[[@B3], [@B13]\]. The distribution of symptoms and signs according to "Korean Standard PIs for Stroke-III," which are parameters to decide the pattern of stroke \[[@B1]\], is shown in [Table 2](#tab2){ref-type="table"}. Among pulse diagnoses, the ratio of subjects with slippery pulse in DP pattern was significantly higher (54.8%) than that in non-DP pattern (38.2%) (*P* = 0.0489). In contrast, the fraction of subjects exhibiting weak pulse was significantly lower in DP pattern (*P* = 0.0073).

To find metabolite levels in plasma that could differentiate non-DP and DP patterns, we performed UHPLC-MS analysis ([Figure 1](#fig1){ref-type="fig"}). A list of metabolites present in significantly different levels in plasma of non-DP and DP patterns is presented in [Table 3](#tab3){ref-type="table"}. Three abundant metabolites, detected as ions of *m*/*z* 520.366, 1039.724, and 1043.763, in positive-ion mode and *m*/*z* 590.335 in negative-ion mode were significantly lower in the DP pattern relative to the non-DP pattern. However, most differentiating metabolites were present at much lower levels or were removed by the abundance threshold of 20 ion counts.

To identify each differentiating metabolite, public databases were searched using ion masses determined using both positive-ion and negative-ion modes. Phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) lipids were identified from positive-ion mode data ([Table 4](#tab4){ref-type="table"}). For example, the mean normalized peak areas of LPC (18 : 2; 9Z, 12Z) and LPC (20 : 3), detected as *m*/*z* 520.366 and 546.399, were 282 and 35 in DP pattern and were significantly lower than 304 and 41 in non-DP pattern (*P* = 0.010 and *P* = 0.034, resp.). Additional LPCs with unsaturated fatty acid, LPC (20 : 4) and LPC (18 : 1), also showed a tendency to be lower in DP than non-DP pattern, but without significance (*P* = 0.070 and *P* = 0.77, resp.). Otherwise, levels of LPCs without double bond, LPC (14 : 0), LPC (16 : 0), and LPC (18 : 0), were not different between two groups.

In the negative-ion mode data, a metabolite detected as *m*/*z*  590.335 was significantly lower in DP pattern (*P* = 0.017) and was identified as the formate ion adduct of LPC (20 : 3), confirming the result from positive-ion mode. Free fatty acids (FFA) and lysophosphatidylethanolamine (LPE), which were mainly detected in negative-ion mode analyses, were not different in the two patterns ([Table 5](#tab5){ref-type="table"}). Only LPE(18:2) showed a tendency to be lower in the DP pattern (*P* = 0.065).

4. Discussion {#sec4}
=============

PI presents a comprehensive system for the diagnosis of disease and is based on the patient\'s signs and symptoms. TKM doctors determine the cause, nature, and treatment of the illness depending on signs and symptoms in patients and use this information to provide individualized treatment to patients, who have the same disease \[[@B3]\]. This approach is similar to what has been described as personalized medicine, which has recently emphasized that patients should receive different treatments according to the patient\'s individual condition to increase the positive effect of treatment and reduce adverse effects \[[@B25], [@B26]\]. But general concepts between PI and personalized medicine are different. PI focuses on the signs and symptoms in patients to define a phenotype that guides treatment selection. Much of the emphasis of modern personalized medicine is based on the genetic background, or genotype, of each patient \[[@B3], [@B27]\]. Therefore, studies to establish relationships between PI and personalized medicine have been performed \[[@B10], [@B11], [@B13]\].

In TKM, stroke is classified into four standard subtypes according to PI: QD, DP, YD, and FH based on position, internal or external etiology, or observations of affected organ. DP, which is classified by etiology, is a combination of phlegm and internal dampness causing disease. Major symptoms of the DP pattern include anorexia, dyspepsia, dizziness, headache, and heaviness \[[@B28]\]. However, not all patients with DP pattern have all of these symptoms, and subjects with other patterns often exhibit some of the same symptoms. For example, only 15% of subjects had dizziness with nausea, considered a major indicator in the DP pattern, and this ratio was not different in subjects with non-DP pattern. Slippery pulse, which is an important factor for the diagnosis of DP pattern and significantly high ratio at DP pattern, occurred in the non-DP pattern ([Table 2](#tab2){ref-type="table"}). These complexities of sign and symptoms complicate PI diagnosis and may cause diagnostic error between TKM doctors. Previous studies reported that concordance rates between two expert TKM doctors about PI diagnosis for stroke, pulse, or tongue diagnosis were 70--90%, which means that the diagnostic error may always be implied \[[@B29]--[@B31]\]. For these reasons, reliable biomarkers for more accurate diagnosis of PI are needed.

Metabolomics provides powerful tools to measure and identify metabolic biomarkers from biofluids, and earlier studies to explain PI using the change in metabolite levels were performed in China \[[@B21], [@B22]\]. In this study, we elucidated UHPLC-MS analysis from plasma of the subjects with CI to find metabolites related with DP pattern of stroke ([Figure 1](#fig1){ref-type="fig"}). From the total of 612 peaks corresponding to specific mass-retention time pairs, 21 metabolite peaks showed significant differences in the levels between DP and non-DP patterns ([Table 3](#tab3){ref-type="table"}). In addition, searches of open metabolome databases allowed annotation of 57 major metabolites detected using this protocol (Tables [4](#tab4){ref-type="table"} and [5](#tab5){ref-type="table"}). The primary conclusions are that the levels of LPC (18 : 2, 9Z, 12Z) and LPC (20 : 3) were significantly lower in DP pattern than non-DP pattern (*P* = 0.010 and 0.034, resp.), and LPC (20 : 4) and LPC (18 : 1) showed a tendency to decrease in DP pattern (*P* = 0.070 and *P* = 0.077).

Lysophosphatidylcholines (LPCs), called lysolecithins, are a class of phospholipids derived from phosphatidylcholines and produced by two pathways. First is the result from partial hydrolysis of phosphatidylcholine, so that one of the fatty acids is removed by the action of phospholipase A2 \[[@B32]\]. A second pathway for LPC formation occurs by the transfer of one fatty acid of phosphatidylcholine to cholesterol by lecithin-cholesterol acyltransferase (LCAT), which is an enzyme that converts free cholesterol into cholesteryl ester. Cholesteryl ester is a more hydrophobic form of cholesterol that is sequestered into the core of a lipoprotein particle \[[@B33]\] and into liver.

Until now, relationships between plasma levels of LPCs and DP pattern were not known, but earlier reports suggested the possibility of such correlations. It was known that DP pattern was related to obesity and hyperlipidemia \[[@B3], [@B8], [@B9]\], and some metabolomic analyses showed that plasma LPC levels were also associated with obesity \[[@B34]--[@B37]\]. Barber et al. and Kim et al. reported that plasma levels of LPCs with one or two double bonds such as lyso (16 : 1), LPC (18 : 1), LPC (18 : 2), and LPC (20 : 1) were significantly reduced in high-fat diet-induced obese mice \[[@B35], [@B36]\], In another study among overweight/obese subjects performed by Kim et al., LPC (18 : 1), LPC (18 : 2), and LPC (20 : 2) were decreased in the plasma of overweight/obese subjects \[[@B37]\]. Of particular note in these studies was the saturated LPC (18 : 0), that increased in obese subjects and obese mice model \[[@B36], [@B37]\], and these results parallel the findings in the current investigation ([Table 4](#tab4){ref-type="table"}).

This study showed, for the first time, that some LPCs in plasma were associated with DP pattern in CI patient population. However, this study included several limitations. First, this is a simple cross-sectional study, and the subjects enrolled in this study were very acute patients. Second, this study does not have a sufficient sample size to generalize the relationship between plasma metabolites and DP pattern. Third, the PI was limited to stroke diagnoses. The lack of evidence on the accuracy of PI forced us to perform an observational study, not allowing a randomized controlled trial. Despite of these limitations, this study provided metabolic information about DP patterns, and further studies should be performed in subjects of another large population to generalize the conclusions of this study.
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![Chromatographic pattern of human plasma metabolite in ESI-positive (a) and ESI-negative mode (b) generated using UHPLC-MS analysis.](ECAM2013-517018.001){#fig1}

###### 

General characteristics of subjects.

  --------------------------------------------------------------------------------------------------------
  Characteristics               Non-DP                          DP                              *P*
  ----------------------------- ------------------------------- ------------------------------- ----------
  *N*                           68                              73                               

  Gender (M/F)                  38 (55.9)/30 (44.1)\*           36 (49.3)/37 (50.7)             0.501

  Age (year)                    67.50 ± 11.43                   69.73 ± 11.07                   0.213^b^

  TOAST (LAA/CE/SVO/SOE/SUE)    15 (22.1)/1 (1.5)/43 (63.2)\    17 (23.3)/4 (5.5)45 (61.6)\     0.300
                                /3 (4.4)/6 (8.8)                /0 (0.0)/7 (9.6)                

  Weight (kg)                   63.18 ± 11.49^\#^               63.67 ± 10.63                   0.799^a^

  BMI (kg/m^2^)                 24.40 ± 3.75                    24.43 ± 3.50                    0.968^a^

  Smoking (none/strop/active)   33 (48.5)/11 (16.2)/24 (35.3)   36 (49.3)/7 (9.6)/30 (41.1)     0.470

  Drinking (none/stop/active)   21 (30.9)/11 (16.2)/36 (52.9)   25 (34.2)/15 (20.5)/33 (45.2)   0.632

  History disease                                                                                

   TIA                          7 (10.3)                        8 (11.1)                        1.000

   Hypertension                 37 (54.4)                       36 (49.3)                       0.614

   Hyperlipidemia               6 (8.8)                         7 (9.6)                         1.000

   Heart disease                4 (5.9)                         2 (2.8)                         0.429

  Serum parameters                                                                               

   GOT (U/dL)                   23.51 ± 9.25                    22.97 ± 6.13                    0.666^b^

   GPT (U/dL)                   20.26 ± 10.10                   20.52 ± 8.50                    0.623^b^

   Total cholesterol (mg/dL)    193.66 ± 41.89                  197.14 ± 43.83                  0.632^a^

   Triglyceride (mg/dL)         192.51 ± 119.82                 187.63 ± 172.77                 0.176^b^

   HDL-cholesterol (mg/dL)      42.97 ± 10.64                   43.34 ± 10.47                   0.735^b^

   LDL-cholesterol (mg/dL)      113.18 ± 35.32                  119.25 ± 38.19                  0.344^a^

   Blood sugar (mg/dL)          116.46 ± 33.68                  117.21 ± 39.63                  0.835^b^
  --------------------------------------------------------------------------------------------------------

\*indicates the number of subjects (%), and ^\#^indicates the value of mean ± SD. The *P* value of categorized variables was calculated by chi-squared test or Fisher\'s test, and continuous variables were analyzed by a student\'s *t*-test (a) or Mann-Whitney *U* test (b) after a normality test and compared with the non-DP group. DP: Dampness-phlegm, BMI: body mass index, TIA: transient ischemic attack, GOT: glutamic oxaloacetic transaminase, GPT: glutamic pyruvate transaminase.

###### 

Difference distribution of symptoms/signs between Dampness-phlegm and non-Dampness-phlegm.

  Symptoms and signs                   Non-DP (*n* = 68)   DP (*n* = 73)   *P*
  ------------------------------------ ------------------- --------------- --------
  Vexation and insomnia                14 (20.59)          9 (12.33)       0.1847
  Reddened complexion                  27 (39.71)          28 (38.36)      0.8696
  Blood-shot eyes                      8 (11.76)           10 (13.7)       0.731
  Wheezing in the throat with sputum   14 (20.59)          18 (24.66)      0.5643
  Fetid mouth odor                     15 (22.06)          12 (16.44)      0.3967
  Thirst                               26 (38.24)          24 (32.88)      0.5063
  Red tongue                           28 (41.18)          25 (34.25)      0.3959
  Yellow fur                           13 (19.12)          21 (28.77)      0.1808
  Thick fur                            23 (33.82)          36 (49.32)      0.0624
  Heat vexation in the chest           14 (20.59)          12 (16.44)      0.5255
  Turbid urine                         8 (11.76)           14 (19.18)      0.2255
  Rapid pulse                          17 (25)             19 (26.03)      0.8888
  Strong pulse                         26 (38.24)          33 (45.21)      0.4018
  Surging pulse                        7 (10.29)           4 (5.48)        0.2868
  Heat vexation and aversion to heat   20 (29.41)          21 (28.77)      0.9329
  Heat in the palms and soles          7 (10.29)           5 (6.85)        0.4639
  Vexing heat in the extremities       4 (5.88)            3 (4.11)        0.7113
  Pale face and red zygomatic site     13 (19.12)          6 (8.22)        0.0583
  Dry mouth                            40 (58.82)          33 (45.21)      0.1059
  Dry fur                              10 (14.71)          19 (26.03)      0.0965
  Bare and red tongue like a mirror    4 (5.88)            2 (2.74)        0.4289
  Night sweating                       5 (7.35)            9 (12.33)       0.3235
  Tidal fever                          4 (5.88)            2 (2.74)        0.4289
  Thin                                 14 (20.59)          17 (23.29)      0.6989
  Drowsiness, likes to lie down        14 (20.59)          10 (13.7)       0.2767
  Feels powerless and lazy             30 (44.12)          28 (38.36)      0.4872
  Looks powerless and lazy             27 (39.71)          29 (39.73)      0.9981
  Pale complexion                      6 (8.82)            5 (6.85)        0.6623
  Reluctance to speak                  6 (8.82)            14 (19.18)      0.0782
  Pale tongue                          14 (20.59)          12 (16.44)      0.5255
  Teeth-marked tongue                  8 (11.76)           9 (12.33)       0.9181
  Slow pulse                           7 (10.29)           13 (17.81)      0.2013
  Weak pulse                           10 (14.71)          10 (13.7)       0.8640
  Fine pulse                           9 (13.24)           1 (1.37)        0.0073
  Reversed cold in the extremities     7 (10.29)           7 (9.59)        0.8887
  Sallow complexion                    20 (29.41)          23 (31.51)      0.7872
  Dark inferior palpebral              14 (20.59)          17 (23.29)      0.6989
  Dizziness with nausea                11 (16.18)          11 (15.07)      0.8562
  White fur                            42 (61.76)          49 (67.12)      0.5063
  Enlarged tongue                      12 (17.65)          10 (13.7)       0.5185
  Slippery pulse                       26 (38.24)          40 (54.79)      0.0489
  Heavy                                27 (39.71)          26 (35.62)      0.6164

Data presented the number of subjects (%) with symptoms/signs. *P* value was calculated by chi-squared test or Fisher\'s test.

###### 

List of metabolites exhibiting different levels in plasma between Dampness phlegm and non-Dampness phlegm.

  Retention time (min)   Mass (*m/z*)   Non-DP           DP               *P*
  ---------------------- -------------- ---------------- ---------------- -------
  ES (+) mode                                                              
   20.04                 1461.2680      6.61 ± 1.43      7.38 ± 2.09      0.009
   17.18                 1039.724       153.13 ± 44.87   134.44 ± 52.43   0.010
   17.15                 520.3663       304.62 ± 48.29   282.22 ± 53.29   0.015
   20.27                 1494.291       18.50 ± 4.16     20.03 ± 4.99     0.022
   17.3                  502.3353       15.82 ± 5.11     14.21 ± 4.05     0.024
   17.46                 546.3991       41.14 ± 17.33    35.35 ± 14.02    0.034
   19.71                 1376.208       20.36 ± 6.07     23.05 ± 8.81     0.037
   18.35                 269.2497       4.13 ± 1.26      3.66 ± 1.15      0.042
   17.69                 1043.763       113.36 ± 46.83   96.79 ± 36.09    0.044
   21.13                 237.1001       26.71 ± 11.22    30.31 ± 10.32    0.046
   17.68                 1565.1790      4.15 ± 2.49      3.33 ± 1.53      0.047
   29.01                 195.0539       5.93 ± 1.88      6.57 ± 1.97      0.048
  ES (−) mode                                                              
   17.14                 1019.5881      10.58 ± 5.27     8.77 ± 5.09      0.010
   0.6                   444.6674       1.32 ± 0.95      1.55 ± 0.82      0.013
   0.53                  740.8311       5.84 ± 2.06      6.63 ± 2.25      0.015
   17.5                  590.3351       104.35 ± 42.97   88.28 ± 38.06    0.017
   29.23                 599.3050       2.50 ± 0.82      2.20 ± 0.69      0.015
   29.23                 288.1364       3.15 ± 1.06      3.47 ± 1.01      0.029
   0.53                  462.8737       1.23 ± 0.49      1.44 ± 0.59      0.032
   17.53                 658.3196       4.30 ± 1.33      3.89 ± 0.98      0.038
   19.87                 961.5879       7.01 ± 3.20      8.21 ± 3.71      0.042

Data are presented as mean normalized peak areas ± SD. The *P* value was calculated by Mann-Whitney *U* test.

###### 

Identification and quantification of metabolites in human plasma using UHPLC-MS and electrospray ionization in positive-ion mode.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Retention\   Common name                 Formula of\              Measured mass\   Theoretical mass\   Mass error\   Non-DP             DP               *P*
  time\                                    \[M+H\]^+^               (*m/z*)          (*m/z*)             (Da)                                              
  (min)                                                                                                                                                    
  ------------ --------------------------- ------------------------ ---------------- ------------------- ------------- ------------------ ---------------- -------
  16.55        LPC(14:0)                   C~22~H~47~NO~7~P^+^      468.35           468.31              +0.04         21.87 ± 11.51^a^   22.95 ± 9.12     0.145

  16.86        LPC(16:1 (9Z))              C~24~H~49~NO~7~P^+^      494.36           494.32              +0.04         58.80 ± 35.99      56.53 ± 27.33    0.671

  17.08        LPC(22:6)                   C~30~H~51~NO~7~P^+^      568.38           568.34              +0.04         75.58 ± 30.32      77.35 ± 37.30    0.961

  17.12        LPC(20:4)                   C~28~H~51~NO~7~P^+^      544.37           544.34              +0.03         104.65 ± 31.01     94.62 ± 33.85    0.070

  17.15        LPC(18:2(9Z, 12Z))          C~26~H~51~NO~7~P^+^      520.36           520.34              +0.02         304.62 ± 48.29     282.22 ± 53.29   0.010

  17.15        unknown                                              1063.75                                            45.49 ± 17.50      40.35 ± 17.42    0.058

  17.46        LPC(20:3)                   C~28~H~53~NO~7~P^+^      546.39           546.35              +0.04         41.14 ± 17.33      35.35 ± 14.02    0.034

  17.51        LPC(16:0)                   C~24~H~51~NO~7~P^+^      496.36           496.34              +0.02         530.37 ± 56.28     533.84 ± 64.59   0.583

  17.69        LPC(18:1)                   C~26~H~53~NO~7~P^+^      522.38           522.36              +0.02         261.34 ± 38.55     249.65 ± 39.38   0.077

  18.21        LPC(18:0)                   C~26~H~55~NO~7~P^+^      524.39           524.37              +0.02         398.11 ± 41.16     402.10 ± 52.47   0.391

  19.10        Dioctyl phthalate\          C~24~H~39~O~4~ ^+^       391.31           391.28              +0.03         31.27 ± 5.95       31.27 ± 4.95     0.817
               (plasticizer contaminant)                                                                                                                   

  19.38        DG(40:4)                    C~43~H~77~O~5~ ^+^       673.58           673.58              +0.007        32.77 ± 15.44      36.78 ± 19.95    0.306

  19.67        DG(40:3)                    C~43~H~79~O~5~ ^+^       675.58           675.59              -0.01         228.01 ± 38.68     229.73 ± 45.96   0.812

  19.73        DG(42:4)                    C~45~H~81~O~5~ ^+^       701.59           701.60              −0.01         289.45 ± 45.60     289.82 ± 44.59   0.961

  19.85        PC(36:5)                    C~44~H~79~NO~8~P^+^      780.59           780.55              +0.04         213.70 ± 45.71     224.66 ± 45.41   0.156

  19.90        PC(34:3)                    C~42~H~79~NO~8~P^+^      756.61           756.55              +0.06         57.74 ± 29.96      58.82 ± 28.32    0.840

  19.95        PC(38:6)                    C~46~H~81~NO~8~P^+^      806.61           806.56              +0.05         219.88 ± 37.58     228.46 ± 45.82   0.501

  19.99        DG(42:3)                    C~45~H~83~O~5~ ^+^       703.61           703.62              −0.01         172.78 ± 29.19     179.24 ± 41.33   0.564

  20.00        Unknown                                              1485.24                                            63.66 ± 25.34      66.75 ± 23.35    0.536

  20.01        PC(36:4)                    C~44~H~81~NO~8~P^+^      782.62           782.57              +0.05         131.29 ± 18.25     128.28 ± 22.48   0.095

  20.08        PC(38:5)                    C~46~H~83~NO~8~P^+^      808.66           808.59              +0.07         30.93 ± 11.17      32.02 ± 13.12    0.760

  20.09        PC(34:2)                    C~42~H~81~NO~8~P^+^      758.60           758.57              +0.03         195.39 ± 23.93     197.90 ± 27.36   0.565

  20.15        PC(36:3)                    C~44~H~83~NO~8~P^+^      784.63           784.58              +0.045        135.50 ± 23.95     133.31 ± 23.26   0.300

  20.30        PC(34:1)                    C~42~H~83~NO~8~P^+^      760.63           760.58              +0.05         149.14 ± 26.43     154.41 ± 26.00   0.235

  20.32        PC(38:4)                    C~46~H~85~NO~8~P^+^      810.68           810.60              +0.08         49.85 ± 13.02      49.02 ± 13.32    0.638

  20.37        PC(36:2)                    C~44~H~85~NO~8~P^+^      786.64           786.60              +0.04         168.87 ± 19.57     170.71 ± 25.72   0.635

  20.43        PC(38:3)                    C~46~H~87~NO~8~P^+^      812.68           812.62              +0.06         60.73 ± 26.71      55.31 ± 22.62    0.149

  20.78        SM(d18:1/24:1(15Z))         C~47~H~94~N~2~O~6~P^+^   813.73           813.68              +0.05         132.91 ± 52.04     131.24 ± 59.93   0.704

  20.79        SM(d18:0/22:1(13Z))         C~45~H~92~N~2~O~6~P^+^   787.72           787.67              +0.05         50.88 ± 40.64      44.42 ± 39.20    0.217
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Data are presented as mean ± SD. The *P* value was calculated by Mann-Whitney *U* test. LPC: lysophosphatidylcholine; PC: phosphatidylcholine; DG: diacylglycerol; SM: sphingomyelin.

###### 

Identification and quantification of metabolites in human plasma using UHPLC-MS and electrospray ionization in negative-ion mode.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Retention\   Common name                     Formula of\           Measured mass\   Theoretical mass\   Mass error\   Non-DP              DP                *P*
  time (min)                                   \[M−H\]^−^            (*m/z*)          (*m/z*)             (Da)                                                
  ------------ ------------------------------- --------------------- ---------------- ------------------- ------------- ------------------- ----------------- -------
  0.64         unknown                                               291.08                                             122.96 ± 70.25^a^   136.14 ± 107.74   0.869

  17.10        LPE(22:6)                       C~27~H~43~NO~7~P^−^   524.27           524.28              \<0.01        65.99 ± 30.35       61.52 ± 25.40     0.419

  17.17        LPE(20:4)                       C~25~H~43~NO~7~P^−^   500.27           500.27              \<0.01        45.65 ± 20.26       40.26 ± 17.24     0.065

  17.23        LPE(18:2)                       C~23~H~43~NO~7~P^−^   476.27           476.28              \<0.01        70.53 ± 34.49       65.03 ± 35.97     0.289

  17.69        LPE(16:0)                       C~21~H~43~NO~7~P^−^   452.27           452.28              \<0.01        48.60 ± 17.28       46.68 ± 18.35     0.258

  17.88        LPE(18:1)                       C~23~H~45~NO~7~P^−^   478.29           478.29              \<0.01        27.78 ± 18.78       24.01 ± 12.01     0.409

  18.32        Eicosapentaenoic acid (C20:5)   C~20~H~29~O~2~ ^−^    301.21           301.22              \<0.01        47.59 ± 31.47       48.31 ± 27.00     0.520

  18.37        Linolenic acid (C18:3)          C~18~H~29~O~2~ ^−^    277.21           277.22              \<0.01        58.12 ± 50.50       64.84 ± 64.66     0.495

  18.64        Docosahexaenoic acid (C22:6)    C~22~H~31~O~2~ ^−^    327.23           327.23              \<0.01        268.96 ± 121.50     294.55 ± 116.64   0.093

  18.68        Free fatty acid (C16:1)         C~16~H~29~O~2~ ^−^    253.21           253.22              \<0.01        83.04 ± 78.33       74.83 ± 63.94     0.901

  18.77        Arachidonic acid (C20:4)        C~20~H~31~O~2~ ^−^    303.23           303.23              \<0.01        161.10 ± 72.52      149.19 ± 77.86    0.306

  18.86        Linoleic acid (C18:2)           C~18~H~31~O~2~ ^−^    279.23           279.23              \<0.01        276.78 ± 191.57     279.87 ± 161.58   0.635

  18.93        Docosapentaenoic acid (C22:5)   C~22~H~33~O~2~ ^−^    329.25           329.25              \<0.01        32.17 ± 23.16       31.04 ± 18.84     0.749

  19.04        Free fatty acid (C20:3)         C~20~H~33~O~2~ ^−^    305.25           305.25              \<0.01        29.70 ± 19.08       29.47 ± 22.32     0.612

  19.18        DG(30:1)                        C~33~H~61~O~5~ ^−^    537.41           537.45              −0.04         17.87 ± 9.91        19.65 ± 9.45      0.176

  19.27        Palmitic acid (C16:0)           C~16~H~31~O~2~ ^−^    255.23           255.23              \<0.01        218.29 ± 140.27     209.29 ± 147.29   0.626

  19.32        DG(30:0)                        C~33~H~63~O~5~ ^−^    539.42           539.46              −0.04         11.81 ± 7.63        15.08 ± 16.86     0.440

  19.36        Oleic acid (C18:1)              C~18~H~33~O~2~ ^−^    281.25           281.25              \<0.01        402.57 ± 311.69     378.81 ± 270.00   0.875

  19.55        unknown                                               393.27                                             63.50 ± 20.78       65.85 ± 22.13     0.641

  19.57        MG(22:5)                        C~25~H~39~O~4~ ^−^    403.30           403.28              +0.02         69.14 ± 27.41       67.50 ± 31.95     0.405

  19.62        Free fatty acid (C17:0)         C~17~H~33~O~2~ ^−^    269.24           269.25              −0.01         20.24 ± 13.09       21.04 ± 14.72     0.862

  19.86        unknown                                               364.49                                             54.03 ± 18.02       49.21 ± 15.44     0.054

  19.89        Stearic acid (C18:0)            C~18~H~35~O~2~ ^−^    283.261          283.264             −0.003        243.29 ± 118.20     220.01 ± 101.87   0.212
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Data are presented as mean ± SD. The *P* value was calculated by Mann-Whitney *U*-test. LPE: lysophosphatidylethanolamine; DG: diacylglycerol, MG: monoacylglycerol; PE: phosphatidylethanolamine.

[^1]: Academic Editor: MinKyun Na
